EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis

Nouman Aziz, Waseem Nabi, Hafiz Muhammad Umer, Faiza Khan, Hira Habib, Adeena Musheer, Sukhrob Makhkamov, Seyed Mohammad Nahidi, Roha Saeed Memon, Faiz Anwer, Moazzam Shahzad

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.07.016 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Nouman Aziz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Wyckoff Heights Medical Center, Brooklyn, NY. Electronic address: NAziz@wyckoffhospital.org. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Platelet Transfusion, Receptors, Thrombopoietin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thrombocytopenia in myelodysplastic syndromes (MDS) is associated with bleeding complications, transfusion dependence, and reduced quality of life. While platelet transfusions remain standard care, they carry limitations including short durability, alloimmunization, and infection risk. Thrombopoietin receptor agonists (TPO-RAs), such as eltrombopagand romiplostim, have emerged as potential alternatives, but their efficacy and safety remain incompletely defined. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing TPO-RAs versus placebo in patients with MDS. Searches were performed across PubMed, EMBASE, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov from inception to January 4, 2025, following PRISMA 2009 guidelines. Eligible trials included adult patients with MDS receiving TPO-RAs with standardized background therapy. Outcomes included platelet transfusion incidence (primary), overall response, AML transformation, severe bleeding, mortality, hematologic improvement, and overall survival. Pooled relative risks (RR) and 95% confidence intervals (CI) were calculated using random-effects models. Heterogeneity was assessed using the I² statistic. RESULTS: Ten RCTs involving 908 patients were included. TPO-RA treatment significantly reduced platelet transfusion incidence (RR 0.67, 95% CI, 0.54-0.86; I² = 10%). Subgroup analysis showed similar reductions with eltrombopag (RR: 0.74; 95% CI, 0.45-1.21) and romiplostim (RR: 0.66; 95% CI, 0.46-0.95). No statistically significant differences were found in overall response (RR 1.09, 95% CI, 0.73-1.64), AML transformation (RR 1.16, 95% CI, 0.88-1.52), grade ≥ 3 bleeding (RR 0.73, 95% CI, 0.47-1.12), hematologic improvement (RR 1.05, 95% CI, 0.84-1.33), overall survival (RR 0.88, 95% CI, 0.63-1.23) or mortality (RR 1.03, 95% CI, 0.90-1.18). CONCLUSION: TPO-RAs significantly reduce platelet transfusion requirements in patients with MDS without increasing risks of AML progression or mortality. These agents provide effective supportive care for thrombocytopenic patients but do not confer survival or disease-modifying benefits. Future studies should investigate long-term outcomes, quality of life, and combination strategies with other disease-modifying therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesPlatelet TransfusionReceptors, ThrombopoietinHumansThrombopoietinRandomized Controlled Trials as TopicReceptors, FcRecombinant Fusion ProteinsHydrazinesThrombocytopeniaBenzoatesPyrazoles

Stichwörter der Autor:innen

AMLAcute myeloid leukemia transformationMDSTPO-RAThrombocytopenia

Substanzen

Receptors, ThrombopoietinThrombopoietinromiplostimReceptors, FcRecombinant Fusion ProteinsHydrazineseltrombopagBenzoatesPyrazoles

Autor:innen und Institutionen

  • Wyckoff Heights Medical Center, Brooklyn, NY. Electronic address: NAziz@wyckoffhospital.org.
  • Wyckoff Heights Medical Center, Brooklyn, NY.
  • King Edward Medical University, Lahore, Pakistan.
  • Allama Iqbal Medical College, Lahore, Pakistan.
  • Dow Medical University, Karachi, Pakistan.
  • Jefferson Health Northeast, Philadelphia, PA.

Zitieren

APA

Aziz, N., Nabi, W., Umer, H. M., Khan, F., Habib, H., Musheer, A., Makhkamov, S., Nahidi, S. M., Memon, R. S., Anwer, F., & Shahzad, M. (2025). Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.07.016

Vancouver

Aziz N, Nabi W, Umer HM, Khan F, Habib H, Musheer A, et al. Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.07.016

BibTeX
@article{Aziz2025,
  author = {Aziz, Nouman and Nabi, Waseem and Umer, Hafiz Muhammad and Khan, Faiza and Habib, Hira and Musheer, Adeena and Makhkamov, Sukhrob and Nahidi, Seyed Mohammad and Memon, Roha Saeed and Anwer, Faiz and Shahzad, Moazzam},
  title = {Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.07.016}
}
Kostenlos starten →